Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER: Pirfenidone to prevent fibrosis in ARDS
2020-005306-25Phase 3Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pirfenidone in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Ventilator‑free days at day 28. Started Jun 2021; status: active.
02
Drugs
pirfenidone
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-005306-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005306-25.